Innovation Through Collaboration



NIH NATIONAL INSTITUTES OF HEALTH Technology Transfer Center

- > Serves as the United States' Medical Research Agency
- > NIH's Impact Worldwide:
 - Driving economic growth and productivity
 - Improving health by promoting treatment and prevention
- > 27 Institutes and Centers
- Each with its own disease focus
- > Connects NIH researchers and external partners
 - Exclusive/Non-exclusive licenses
 - Clinical Validation (Clinical Trial Agreements; CTAs)
 - Co-Development (Cooperative Research and Development Agreements;
 CRADAs)
 - Low-cost Tools/Reagents (Material Transfer Agreements; MTAs)





Licensing/Collaboration Agreements with the National Cancer Institute



- > Address technology gaps
- > Address knowledge gaps
- > Enhance pipeline



- \$ Boost product commercialization
- \$ Expand addressable markets

NIH Value Proposition:

Technical, Commercial, Economic Development


- > >\$6B Product sales from licensed NIH IP (2020)
- > Numerous advantages to working with us:
 - ✓ No up-front equity and 0-10% overhead rate
 - ✓ Won't take your IP
 - √ Validate your technology and/or test in humans
 - ✓ World-renowned researchers and resources
 - ✓ Prestige factor: Collaboration = higher company profile













Partnering with NIH Offers Significant Commercialization Potential

Acquisition of Licensee



Kite acquired by



for US \$11B



acquired by TURNSTONE - terms undisclosed (2021)

Funding of Licensee

Rakuten Medical 2013 NCI License > \$13M Series A > \$55M Series B > \$284M Series C





2020 NCI License \$1.8M Seed Closing

Collaborators and Licenses

| Organization | Product | 2020 Worldwide Sales |
|----------------------------|---|----------------------|
| MERCK - | GARDASIL. | US \$3.6B |
| janssen 🖯 | PREZISTA® (darunavir) tablets | US \$2.2B |
| obbyie sobi AstraZeneca | SYNAGIS* PALIVIZUMAB | US \$1.6B |
| Takeda | VELCADE® (bortezomib) | US \$1.3B |
| Eisai | Halaven® (eribulin mesylate) Injection 0.5 mg/mL | US \$595M |

NIH Technology Portfolio

- > Assets available for licensing/collaboration:
 - Small molecules
 - Biologics
 - Devices
 - Diagnostics

- Vaccines
- Wearables and Digital health
- Software
- Research tools (cells, mice, etc.)
- > Pre-clinical and clinical stage technologies

Website

www.ott.nih.gov

- Listserv distributions of new opportunities
- Technologies available for licensing and co-development

General Inquiries

Please reach out to: NCITechTransfer@mail.nih.gov

Social Media



www.linkedin.com/co mpany/intramuralresearch-program-irp/

